TFS HealthScience Expands Global Ophthalmology Unit with New Leadership and Advanced Delivery Models

TFS HealthScience Expands Global Ophthalmology Unit



TFS HealthScience, a notable global Contract Research Organization (CRO), is making concerted efforts to elevate its ophthalmology unit. This expansion is fueled by a new leadership team and advanced operational capabilities tailored to meet the escalating demand for specialized clinical trial execution in eye care. The ophthalmology market is witnessing unprecedented growth, valued at nearly $60 billion in 2023 and projected to surge to $94 billion by 2030. This uptick necessitates CRO partners proficient in managing intricate, global programs.

To address this increasing demand, TFS has adopted a therapeutically aligned operating model, built around a dedicated ophthalmology team with robust expertise across various conditions, including retinal, corneal, and neuro-ophthalmic diseases. Under the guidance of CEO Markus Granlund, TFS has embraced a decentralized structure empowering different therapeutic segments to take full ownership of their deliverables.

Marcia Swank, the newly appointed Vice President and Head of Ophthalmology, emphasizes the urgency for sponsors racing against time to innovate while patients await better treatment options. “As trials grow more complex and technology reshapes the landscape, CROs must evolve to deliver faster, smarter, and always with the patient in focus,

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.